Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well-differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the French Group of Endocrine Tumors (GTE)

(1) CHD Vendée La Roche Sur Yon,La Roche Sur Yon,France

(2) Institut Gustave Roussy,Villejuif,France

(3) Institut de Cancérologie de L'Ouest,Saint Herblain,France

(4) University Hospital of Saint-Etienne,Saint Priest en Jarez,France

(5) Hopital Beaujon, APHP, Université Denis Diderot,Beaujon,France

(6) CHU Rangueil,Toulouse,France

(7) Hospices Civils de Lyon,Lyon,France

(8) University Hospital of Poitiers,Poitiers,France

(9) University Hospital of Angers,Angers,France

(10) Hôpital Robert Debré,Reims Cedex,France

(11) Centre Eugene Marquis,Rennes,France

(12) Institut de Cancérologie Gustave Roussy,Villejuif,France

(13) CHU de Nantes IMAD,Nantes,France

(14) University Hospital Nantes,Nantes,France

This item was part of the New frontiers in pancreatic neoplasias session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019


  • Format
    • Abstract
  • Year
    • 2019